Please login to the form below

Not currently logged in
Email:
Password:

GSK extends deadline for HGS tender

But fails to improve $2.6bn offer for Human Genome Sciences

GlaxoSmithKline (GSK) has extended the deadline for its $2.6bn tender offer to acquire all outstanding shares of Human Genome Sciences to June 29, but has opted not to increase its $13 per share bid.

HGS' management has repeatedly turned down GSK's offer and has been implementing a number of defensive measures to try to thwart the hostile takeover, including a shareholder rights plan that would trigger if GSK's stake in the firm rose above 15 per cent.

By the time the first deadline expired on midnight of June 7, GSK had received tenders for less than 500,000 shares, which represented less than 1 per cent of HGS' outstanding stock, according to the US biotech.

In a statement issued on Friday, GSK said it said its $13 per share bid "represents full and fair value and is in the best interests of both companies' shareholders". Shares in HGS are currently trading at $13.32.

The pharma major reiterated its view that the offer reflects the value of HGS' portfolio, which includes lupus treatment Benlysta (belimumab) - co-marketed by the two companies - as well as investigational drugs darapladib and albiglutide.

Meanwhile, HGS said once again that it was looking at a number of strategic alternatives, including a potential sale of the company.

"This process continues to be active and fully underway," it said, noting that GSK declined to take part and "seeks to circumvent, disrupt and prematurely end the company's process to the disadvantage of HGS stockholders".

Analysts suggested that the deadline was designed to give GSK time to replace HGS' board members with its own candidates, via a consent solicitation process which it started at the end of May. HGS' bylaws include a provision to allow a change in board control without a general meeting.

11th June 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Strategic North

Strategic North is an insight driven healthcare strategic marketing agency, which offers you something a little bit different. Our purpose...

Latest intelligence

BL_Where_Now_20140721_CoverImage.jpg
3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....
Online Physician Communities
How can pharma develop a more customer-centric approach?
Business pressures and customer needs will force pharma to focus on multichannel marketing in the next few years...
Exploring MINT: Part 2 - Indonesia
In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...